🟢 Moleculin Biotech is trading 5% up today ahead of AACR Annamycin pancreatic-cancer data

Moleculin Biotech is trading at $0.60, up +5.15%, ahead of the September 25–28 AACR conference, where new Annamycin pancreatic-cancer data will be presented.

• The abstract is scheduled for publication at 1:00 p.m. ET on September 25, creating a near-term speculative catalyst.
• No separate September 25 clinical-results announcement has been reported; broader markets are only modestly higher.